Perseus Proteomics Inc.
4882・Growth Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The board consists of 8 directors (5 of whom are outside directors), with an outside director ratio of 62.5%. A Compensation Committee has been established, reflecting efforts to ensure independence and transparency. All directors maintained a high attendance rate, attending 14 of 14 board meetings.
Risk Management
The Sustainability Committee, chaired by the Representative Director and President, serves as the core body, with the Disaster Prevention & Safety Committee, Health & Safety Committee, Laboratory Safety Committee, and Information Security Committee established under it. The Company identifies corruption prevention, disasters and infectious diseases, employee safety, and IT security as key risks, and has implemented measures such as formulating BCPs, conducting regular drills, and performing information security assessments.
Shareholder Returns
Has not paid dividends since establishment. The company prioritizes securing funds for R&D and does not intend to pay dividends for the time being. As of the end of FY2023 (ended March 2023), it was not in a financial position permitting dividends under the Companies Act, and is not expected to be in a position to pay dividends until accumulated losses are eliminated.
Dividend Policy
The company has not paid dividends since its establishment and, for the time being, prioritizes securing funds to support the continuous implementation of R&D activities, and therefore does not intend to pay dividends. If dividends of surplus are to be paid, the basic policy is a single year-end dividend once per year, although interim dividends are also permitted under the Articles of Incorporation. As of the end of FY2023 (ended March 2023), the company was not in a financial position permitting dividends under the Companies Act, and even after achieving profitability, it will not be in a position to pay dividends until accumulated losses are eliminated.
ESG
Under the basic policy of "Contributing to global healthcare through cutting-edge antibody technology," the company has set materiality items including the creation of innovative pharmaceuticals, environmental consideration, employee diversity, and strengthened compliance. In FY2026 (ending March 2026), the ratio of female managers stood at 37.5% (target: 50%), and the gender wage gap was 84.8% (target: 100%), with continued initiatives to promote women's advancement.
Last updated: June 30, 2026